Hillevax
Founders
Rob Hershberg, MD, PhD - CEO
Aditya Kohli PhD - COO
Astrid Borkowski, MD - CMO
Founded
2021
Stage
Seed
Invested
2021
Status
IPO

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Hillevax